Primary plasma cell leukemia in the era of new drugs: Has something changed?

Livio Pagano, Luca Baldini, P Musto, Mt Petrucci, Francesco Morabito, T Caravita, F Di Raimondo, Paolo Tosi, S Bringhen, M Offidani, P Omede', A Neri, F D'Auria, Gb Bochicchio, M Cavo, M Boccadoro, A. Palumbo

Risultato della ricerca: Contributo in rivistaArticolo in rivista

14 Citazioni (Scopus)


Primary plasma cell leukemia (PPCL) is a rare and aggressive variant of multiple myeloma. This disease is associated with a very poor prognosis, and unfortunately it has not significantly improved during the last three decades. Autologous stem cell transplantation is generally recommended in eligible patients, but survival in transplanted PPCL patients is significantly lower than that of multiple myeloma. Recent preliminary data indicate that new drugs, in particular lenalidomide and bortezomib, could significantly improve the clinical outcome of PPCL, increasing response rate and duration, as well as survival. In this review we report an updated literature analysis about the current therapeutic scenario of PPCL, with a particular focus on the use of novel agents.
Lingua originaleEnglish
pagine (da-a)141-149
Numero di pagine9
Stato di pubblicazionePubblicato - 2012


  • plasmacell leukemia

Fingerprint Entra nei temi di ricerca di 'Primary plasma cell leukemia in the era of new drugs: Has something changed?'. Insieme formano una fingerprint unica.

Cita questo